Examining variation in interstage mortality rates across the National Pediatric Cardiology Quality Improvement

Katherine E Bates1, Sunkyung Yu1, Ray Lowery1

  • 11Department of Pediatrics and Communicable Diseases,Congenital Heart Center,C.S. Mott Children's Hospital,Ann Arbor,MI,USA.

Insights

Interstage mortality variation in hypoplastic left heart syndrome persists despite improvements. Differences in care practices, not patient risk factors, likely explain survival disparities between pediatric cardiology centers.

Area of Science:

  • Pediatric Cardiology
  • Congenital Heart Disease Research
  • Quality Improvement Science

Background:

  • Interstage mortality for hypoplastic left heart syndrome (HLHS) shows persistent variation across centers.
  • The National Pediatric Cardiology Quality Improvement Collaborative has reduced overall mortality, but center-specific differences remain.
  • It is unclear if these variations are due to patient risk factors or care delivery differences.

Purpose of the Study:

  • To investigate whether differences in baseline risk factors explain the variation in interstage mortality rates among centers.
  • To compare centers with lower interstage mortality to those with higher rates within the National Pediatric Cardiology Quality Improvement Collaborative.

Main Methods:

  • Defined lower-mortality centers (>25 consecutive interstage survivors) and higher-mortality centers (>10% cumulative interstage mortality).
  • Compared established baseline risk factors and perioperative characteristics between these two groups of centers.
  • Utilized multivariable analysis to adjust for potential confounding variables.

Main Results:

  • Seven lower-mortality centers (2.7% mortality) and four higher-mortality centers (13.3% mortality) were identified.
  • Postnatal diagnosis was the only baseline risk factor that differed significantly between groups (18.4% vs. 31.8%).
  • Significant mortality differences persisted even after adjusting for postnatal diagnosis, indicating other factors are involved.

Conclusions:

  • Differences in baseline patient risk factors do not explain the observed variation in interstage mortality for HLHS.
  • Further research is needed to explore variations in care practices and identify specific targets for quality improvement efforts.
  • Understanding and addressing care practice variations is crucial for reducing interstage mortality disparities.
Abstract

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
266
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
320
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
239
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
305
What is Variation?01:14

What is Variation?

Apart from the measures of central tendency, distribution, outliers, and the changing characteristics of data with time, an important characteristic of any data set is its variation or spread. In some data sets, the data values are concentrated closely near the mean; in others, the data values are more widely spread out from the mean.
The range, standard deviation, standard error, and variance are the different measures of variation.
Range: The range is the difference between its maximum and...
18.6K
National Nursing Organizations I01:26

National Nursing Organizations I

Nursing organizations assume a significant role in consistently developing the nursing profession through education, research studies, establishing practice standards, and reforming health policies. Typically, nursing organizations operate at the regional, national, and international levels. For example, the International Council of Nurses (ICN) represents more than 28 million nurses worldwide. In contrast, the American Nurses Association (ANA) is a membership organization representing nurses...
3.1K